THE WOODLANDS, Texas, and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.

德克萨斯州伍德兰（WOODLANDS）和以色列海法（HAIFA），2024年5月7日/PRNewswire/--领先的细胞治疗合同开发和制造组织（CDMO）Cellipont Bioservices和总部位于以色列的私人生物技术公司Adva Biotechnology今天宣布与Adva Biotechnology合作，标志着Adva X3®平台在北美的启动。

The ADVA X3® is an advanced, fully automated platform for manufacturing cell therapies, streamlining processes and reducing costs. This alliance signifies a leap forward in personalized treatment, bringing cutting-edge therapies to patients worldwide..

ADVA X3®是一个先进的全自动化平台，用于制造细胞疗法，简化流程并降低成本。该联盟标志着个性化治疗的飞跃，为全球患者带来了尖端疗法。。

This alliance signifies a leap forward in personalized treatment, bringing cutting-edge therapies to patients worldwide.

该联盟标志着个性化治疗的飞跃，为全球患者带来了尖端疗法。

The ADVA X3® is an all-in-one automated system that simplifies and accelerates the manufacturing of CAR-T therapies from manual to fully automated and cGMP in as little as three months. It represents a major advancement in manufacturing efficiency and quality control, ensuring the delivery of life-saving therapies with minimal user involvement.

ADVA X3®是一个多功能自动化系统，可在短短三个月内简化和加速CAR-T疗法的制造，从手动到全自动和cGMP。它代表了制造效率和质量控制方面的重大进步，确保了以最少的用户参与提供挽救生命的疗法。

Moreover, the ADVA X3® significantly reduces costs, making it accessible to a broader patient population. The unique combination of Cellipont's best-in-class process and manufacturing expertise and purpose-built facility coupled with the ADVA X3® metabolic sensing-based AI-driven automated manufacturing platform allows therapy developers to quickly go from manual processing to fully automated and cGMP.

此外，ADVA X3®显着降低了成本，使更广泛的患者群体可以使用它。Cellipont一流的工艺和制造专业知识以及专门建造的设施与基于ADVA X3®代谢传感的人工智能驱动的自动化制造平台的独特结合，使治疗开发人员能够快速从手动处理过渡到全自动和cGMP。

Additionally, the ADVA X3® system supports cell therapies such as NK, TCR, TIL and exosomes from activation to final cell product..

此外，ADVA X3®系统支持从激活到最终细胞产物的细胞疗法，例如NK，TCR，TIL和外泌体。。

'We're proud to partner with Adva Biotechnology and be the first CDMO in North America to offer the ADVA X3® to clients. The ADVA X3's automation and precision are game changers, enabling us to scale up production and meet the urgent needs of patients,' said Michael O'Mara, COO of Cellipont Bioservices..

“我们很荣幸与Adva Biotechnology合作，成为北美第一家向客户提供Adva X3®的CDMO。Cellipont Bioservices首席运营官迈克尔·奥马拉（MichaelO'Mara）说，ADVA X3的自动化和精确性改变了游戏规则，使我们能够扩大生产规模，满足患者的迫切需求。。

'The collaboration with Cellipont Bioservices is a pivotal moment for us,' said Dr. Ohad Karnieli, CEO of Adva Biotechnology. 'The ADVA X3® embodies our commitment to innovation and patient care, and with Cellipont's expertise, we're set to transform the landscape of cell therapies.'

Adva Biotechnology首席执行官OhadKarnieli博士说，与Cellipont Bioservices的合作对我们来说是一个关键时刻ADVA X3®体现了我们对创新和患者护理的承诺，凭借Cellipont的专业知识，我们将改变细胞疗法的格局。”

Meet Us at ASGCT 2024 in Baltimore, MD

在马里兰州巴尔的摩的ASGCT 2024与我们会面

Both Cellipont Bioservices and Adva Biotechnology will be exhibiting at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place in Baltimore from May 7- 11, 2024. Attendees interested in learning more about the ADVA X3® system and exploring the latest advancements in cell therapy are encouraged to visit our booths (Cellipont Booth #1613, Adva Booth #1841).

Cellipont Bioservices和Adva Biotechnology将于2024年5月7日至11日在巴尔的摩举行的美国基因与细胞治疗学会（ASGCT）年会上展出。鼓励有兴趣进一步了解ADVA X3®系统并探索细胞治疗最新进展的与会者参观我们的展位（Cellipont展位#1613，ADVA展位#1841）。

Representatives from both companies will be available to discuss our collaboration, answer questions, and share insights..

两家公司的代表将可以讨论我们的合作，回答问题并分享见解。。

About Cellipont

关于Cellipont

Cellipont Bioservices is a premier Contract Development and Manufacturing Organization (CDMO) specializing in the advancement of cell therapies. With a team of industry-leading experts, Cellipont is at the forefront of cell therapy development and manufacturing, offering comprehensive solutions from process development, analytical services, to large-scale commercial manufacturing.

Cellipont Bioservices是一家主要的合同开发和制造组织（CDMO），专门从事细胞疗法的发展。Cellipont拥有业界领先的专家团队，处于细胞疗法开发和制造的前沿，提供从工艺开发、分析服务到大规模商业制造的全面解决方案。

Our purpose-built facility, combined with our cutting-edge technology and commitment to quality enable us to support our clients in delivering life-changing cell therapies to patients worldwide. Cellipont Bioservices is dedicated to excellence in all aspects of our operations, ensuring that we not only meet but exceed the expectations of our clients and the communities we serve.

我们专门建造的设施，结合我们的尖端技术和对质量的承诺，使我们能够支持我们的客户向全球患者提供改变生命的细胞疗法。Cellipont Bioservices致力于在运营的各个方面追求卓越，确保我们不仅满足而且超越客户和我们服务的社区的期望。

To learn more, visit www.cellipont.com..

要了解更多信息，请访问www.cellipont.com。。

About Adva Biotechnology

关于Adva Biotechnology

Adva Biotechnology is at the forefront of revolutionizing cell therapy manufacturing. By providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies. Their flagship product, the ADVA platform, is a fully controlled, flexible, and automated cell processing system.

Adva Biotechnology是革新细胞疗法制造业的前沿。它为先进的细胞疗法提供了一个分散、自动化和高效的制造平台。他们的旗舰产品ADVA平台是一个完全受控、灵活且自动化的细胞处理系统。

It leverages the unique CAMP (Continues Adaptive Multi-Parameter) technology, which streamlines autologous cell therapy manufacturing processes. Through automation, optical sensing, and artificial intelligence, Adva Biotechnology aims to remove the manual component from the process, ultimately advancing treatments for various forms of cancer and other conditions.

它利用独特的CAMP（连续自适应多参数）技术，简化了自体细胞疗法的制造过程。通过自动化、光学传感和人工智能，Adva Biotechnology旨在从过程中去除手动成分，最终推进各种形式癌症和其他疾病的治疗。

Their commitment to improving patient outcomes through innovative technology underscores their mission: valuing life and advancing therapies. To learn more, visit www.advabio.com..

他们致力于通过创新技术改善患者预后，这突出了他们的使命：重视生命和推进治疗。欲了解更多信息，请访问www.advabio.com。。

View original content to download multimedia:https://www.prnewswire.com/news-releases/cellipont-bioservices-and-adva-biotechnology-collaborate-to-optimize-cell-therapy-manufacturing-with-the-adva-x3-platform-302138268.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/cellipont-bioservices-and-adva-biotechnology-collaborate-to-optimize-cell-therapy-manufacturing-with-the-adva-x3-platform-302138268.html

SOURCE Cellipont Bioservices

来源：CelliPont生物服务